ARMGO Pharma Receives $1 Million Award for Muscle Dystrophy Treatment

ARMGO Pharma, in collaboration with the Muscular Dystrophy Association, has received a $1 million award for preclinical work on ARM210, a potential treatment for Duchenne muscular dystrophy. The Rycal drug targets the ryanodine receptor to repair calcium leaks in muscle disease. ARMGO Pharma is dedicated to developing small-molecule therapeutics for cardiac, musculoskeletal, and neurological disorders, with its lead Rycal program, ARM036, in phase 2 clinical studies for heart failure and arrhythmias. Les Laboratoires Servier holds development and commercial rights for ARMGO's Rycal drugs outside of the U.S. and Japan.